Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 26, 2017. The document serves as a transaction notification regarding share allocations for Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions.
| Transaction Type | Instrument | Price | Total Volume |
|---|---|---|---|
| Acquisition of Notional Shares | Ordinary Shares (GBP) | £15.99 | 6,576.607 |
| Acquisition of Notional Shares | American Depositary Shares (USD) | $42.29 | 2,000.170 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share allocation arrangements for Independent Non-Executive Directors for the service period of April 1, 2017, to June 30, 2017.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is a regulatory disclosure of director compensation in the form of notional share acquisitions.
Investor Verification Checklist
- Verify the total number of Ordinary Shares and ADSs allocated to directors for the Q2 2017 service period.
- Confirm the transaction price of £15.99 per Ordinary Share and $42.29 per ADS reflects the market value on the transaction date (July 26, 2017).
- Review the company's annual report (Form 20-F) for broader financial performance and strategic outlook, as this filing contains no such data.